Product Description
Ophthalmic levobunolol is used to treat glaucoma, a condition in which increased pressure in the eye can lead to gradual loss of vision. Levobunolol is in a class of medications called beta blockers. It works by decreasing the pressure in the eye. (Sourced from: https://medlineplus.gov/druginfo/meds/a686011.html)
Mechanisms of Action: ADRB1 Antagonist,ADRB2 Antagonist,ADRB3 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Czech | Dominican Republic | Egypt | Finland | France | Germany | Hong Kong | Hungary | India | Ireland | Korea | Malaysia | Malta | Mexico | New Zealand | Pakistan | Peru | Portugal | Russia | Slovenia | South Africa | Spain | Switzerland | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|